NOTE

🌱 created from: bite

BiTE RRMM

• BCMA, also known as tumor necrosis factor receptor superfamily 17 (TNFRSF17) or CD269, is a type III transmembrane glycoprotein that is expressed on mature B-lymphocytes, overexpressed on malignant PCs, and absent in non-hematological tissues.

  • 又稱腫瘤壞死因子受體超家族 17（TNFRSF17）
  • 或 CD269
  • 是一種 III 型跨膜糖蛋白
  • 在成熟的 B 淋巴細胞上表達
  • 在惡性漿細胞上過度表達
  • 在非血液組織中則不存在

• Teclistamab CD3/BCMA R/R MM after ≥4 prior LOT, including an IMiD, PI, and anti-CD38 mAb (2022)

• Talquetamab CD3/GPRC5D R/R MM after ≥4 prior LOT, including an IMiD, PI, and anti-CD38 mAb (2023)

  • MonumenTAL-1

• Elranatamab CD3/BCMA R/R MM after ≥4 prior LOT, including an IMiD, PI, and anti-CD38 mAb (2023)

• CART or BiTE in MM

• Extramedullary Disease: Worse Prognosis

• Toxicity management in bispecific antibiotics in multiple myeloma

Frequency and Duration of bispecific antibiotics